These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 25248874)

  • 1. Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab.
    Pei SN; Chen CH
    Leuk Lymphoma; 2015 Jun; 56(6):1611-8. PubMed ID: 25248874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
    Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
    Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
    J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
    Huang YH; Hsiao LT; Hong YC; Chiou TJ; Yu YB; Gau JP; Liu CY; Yang MH; Tzeng CH; Lee PC; Lin HC; Lee SD
    J Clin Oncol; 2013 Aug; 31(22):2765-72. PubMed ID: 23775967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study.
    Seto WK; Chan TS; Hwang YY; Wong DK; Fung J; Liu KS; Gill H; Lam YF; Lie AK; Lai CL; Kwong YL; Yuen MF
    J Clin Oncol; 2014 Nov; 32(33):3736-43. PubMed ID: 25287829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
    Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
    Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
    Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
    J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late reactivation of hepatitis B virus after rituximab-containing chemotherapy for mantle cell lymphoma: a case report.
    Ciccullo A; Ponziani FR; Maiolo E; Pallavicini F; Pompili M
    Infection; 2019 Apr; 47(2):313-316. PubMed ID: 30368733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma.
    Kusumoto S; Tanaka Y; Mizokami M; Ueda R
    Int J Hematol; 2009 Jul; 90(1):13-23. PubMed ID: 19544079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy.
    Koo YX; Tan DS; Tan IB; Tao M; Chow WC; Lim ST
    Cancer; 2010 Jan; 116(1):115-21. PubMed ID: 19899164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
    Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
    World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients with undetectable serum HBV DNA after treatment with rituximab for lymphoma: a meta-analysis.
    Tang Z; Li X; Wu S; Liu Y; Qiao Y; Xu D; Li J
    Hepatol Int; 2017 Sep; 11(5):429-433. PubMed ID: 28856548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma.
    Matsui T; Kang JH; Nojima M; Tomonari A; Aoki H; Yamazaki H; Yane K; Tsuji K; Andoh S; Andoh S; Sakai H; Maemori M; Maguchi H; Tanaka Y
    J Med Virol; 2013 Nov; 85(11):1900-6. PubMed ID: 23926082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma.
    Loglio A; Viganò M; Grossi G; Labanca S; Goldaniga M; Pompa A; Farina L; Rumi M; Corradini P; Facchetti F; Lunghi G; Baldini L; Lampertico P
    Dig Liver Dis; 2019 Mar; 51(3):419-424. PubMed ID: 30316785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis.
    Mozessohn L; Chan KK; Feld JJ; Hicks LK
    J Viral Hepat; 2015 Oct; 22(10):842-9. PubMed ID: 25765930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.
    Niitsu N; Hagiwara Y; Tanae K; Kohri M; Takahashi N
    J Clin Oncol; 2010 Dec; 28(34):5097-100. PubMed ID: 20837949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy.
    Kusumoto S; Tanaka Y; Ueda R; Mizokami M
    J Gastroenterol; 2011 Jan; 46(1):9-16. PubMed ID: 20924616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The risk of hepatitis B virus reactivation and the role of antiviral prophylaxis in hepatitis B surface antigen negative/hepatitis B core antibody positive patients with diffuse large B-cell lymphoma receiving rituximab-based chemotherapy.
    Lu S; Xu Y; Mu Q; Cao L; Chen J; Zhu Z; Lou Y; Meng H; Qian W; Tong H; Mai W; Huang J; Yu W; Zhao X; Jin J
    Leuk Lymphoma; 2015 Apr; 56(4):1027-32. PubMed ID: 25065698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival.
    Chen KL; Chen J; Rao HL; Guo Y; Huang HQ; Zhang L; Shao JY; Lin TY; Jiang WQ; Zou DH; Hu LY; Wirian ML; Cai QQ
    Chin J Cancer; 2015 May; 34(5):225-34. PubMed ID: 26058465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphoproliferative Disease and Hepatitis B Reactivation: Challenges in the Era of Rapidly Evolving Targeted Therapy.
    Phipps C; Chen Y; Tan D
    Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):5-11. PubMed ID: 26705677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.